洛拉替尼治疗酪氨酸激酶抑制剂难治性ALK阳性非小细胞肺癌伴中枢神经系统转移患者成功妊娠并健康分娩:母胎药代动力学与儿童里程碑发育相关性
本文报告首例在洛拉替尼治疗期间妊娠的转移性ALK阳性非小细胞肺癌患者,孕20周因脑转移复发重新使用低剂量洛拉替尼,肿瘤控制成功且胎儿生长正常。产后20个月随访,母亲维持颅内和全身缓解,婴儿无先天性异常;药代动力学分析和质谱成像证实洛拉替尼可经胎盘转移。
要点
- 首例洛拉替尼治疗期间妊娠的ALK阳性非小细胞肺癌患者报告
- 孕20周重新使用低剂量洛拉替尼后肿瘤控制成功且胎儿生长正常
- 产后20个月母亲维持颅内和全身缓解,婴儿无先天性异常
核心结论
- 本病例凸显了妊娠期使用洛拉替尼的潜在安全性和安全性担忧,以及中枢神经系统优势型ALK阳性非小细胞肺癌的独特性,并提示减剂量洛拉替尼的潜在临床效用。
研究设计与样本
- 病例报告:一例33岁妊娠女性,有7年ALK阳性转移性非小细胞肺癌病史,孕20周因脑转移复发入院。
- 进行了文献回顾以识别所有既往报告的ALK阳性非小细胞肺癌妊娠。
- 进行了洛拉替尼药代动力学采集、测定和分析以及洛拉替尼质谱成像。
主要发现
- 患者在孕4周自行停用洛拉替尼(此前长期疾病控制下已减量),孕20周根据患者偏好重新引入低剂量洛拉替尼,肿瘤控制成功且胎儿生长正常。
- 产后20个月随访,母亲维持颅内和全身缓解,婴儿未观察到先天性异常。
- 围产期药代动力学分析和质谱成像证实洛拉替尼的胎盘转移。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Lorlatinib is the preferred first-line treatment for advanced ALK+ (ALK+) NSCLC on the basis of the 5-year CROWN update. However, the effects of lorlatinib on the fetus and neonate remain unknown. METHODS: We report the first case of a patient with metastatic ALK+ NSCLC who became pregnant during treatment with lorlatinib. A literature review was performed to identify all previously reported pregnancies of ALK+ NSCLC. The collection, determination, and analysis of lorlatinib pharmacokinetics and mass spectroscopy imaging of lorlatinib are both performed. RESULTS: A 33-year-old pregnant woman with a 7-year history of ALK+ metastatic NSCLC was admitted to the hospital with brain metastases recurrence at 20 weeks of gestation. She self-discontinued lorlatinib at 4 weeks of gestation after long-term disease control on a reduced dose. According to the patient's preference, low-dose lorlatinib was reintroduced at 20 weeks, with successful tumor control and normal fetal growth. At 20-month follow-up postpartum, the mother maintained intracranial and systemic remission, and no congenital abnormalities were observed in the baby. Pharmacokinetic analyses and mass spectroscopy imaging peridelivery confirmed the placental transfer of lorlatinib. CONCLUSIONS: The case highlights both the potential safety and safety concerns with the use of lorlatinib during pregnancy, along with the unique nature of central nervous system-dominant ALK+ NSCLC, and the potential clinical utility of dose-reduced lorlatinib.
引用
- Yao Z, Tang M, Jin Y, et al. Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations. J Thorac Oncol. 2025. PMID: 40441332. doi:10.1016/j.jtho.2025.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。